Want to join the conversation?
$REGN and $SNY announced today that European Commission has approved Praluent (alirocumab) for lowering of low-density lipoprotein cholesterol in certain adults with hypercholesterolemia. Praluent was co-developed by $REGN and $SNY and will be available in a single-dose (75 mg or 150 mg) pre-filled pen that patients can self-administer.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.